Frontline treatments in extremely elderly patients with diffuse large B-cell lymphoma: a population-based study in Taiwan, 2010-2015

• Published in: Immunity & ageing 2020-06, Vol.17 (1), p.17-17, Article 17
• Main Authors: Huang, Huai-Hsuan, Ko, Bor-Sheng, Chen, Ho-Min, Chen, Li-Ju, Wang, Chen-Yu, Hsiao, Fei-Yuan
• Format: Article
• Language: English
• Subjects: Age; Aged patients; Analysis; Anthracycline; Anthracyclines; B-cell lymphoma; Care and treatment; Clinical trials; Diffuse large B cell lymphoma; Extremely elderly; Immunotherapy; Lymphocytes B; Lymphoma; Medical prognosis; Monoclonal antibodies; National health insurance; Non-Hodgkin's lymphomas; Online databases; Patients; Population; Population studies; Population-based studies; Radiation therapy; Rituximab; Studies; Survival analysis; Taiwan Cancer registry database; Targeted cancer therapy
• ISSN: 1742-4933; 1742-4933
• DOI: 10.1186/s12979-020-00188-8

The standard frontline therapy for patients with diffuse large B cell lymphoma (DLBCL) is R-CHOP. However, patients older than 80 years are excluded from clinical trials. The importance of rituximab and anthracycline remains unknown in extremely elderly DLBCL patients. Here, we incorporated data from the Taiwan Cancer Registry Database (TCRD), National Health Insurance Research Database (NHIRD), and National Death Registry to evaluate the clinical benefits of rituximab and anthracycline in elderly patients. From the TCRD and NHIRD, we included DLBCL patients aged older than 60 years who received R-CHOP, R-CVP, CHOP, or CVP between 2010 and 2015. Of the 3228 eligible patients, 2559 were between 60 and 79 years (the 60-79 group), and 669 were older than 80 years (the 80+ group). The proportions of patients in the different Ann Arbor stages and the practice settings were similar in both groups. The male-to-female ratio and the Charlson comorbidity index (CCI) scores in the 80+ group were higher than those in the 60-79 group. Patients in the 60-79 group received R-CHOP more frequently than those in the 80+ group. In the 60-79 group, the median age of the patients receiving R-CVP or CVP was older than those receiving R-CHOP or CHOP. In the analysis of overall survival (OS) and time to treatment failure (TTF), R-CHOP, female sex, younger age, lower Ann Arbor stage, lower CCI score, and care at a medical center predicted a favorable prognosis in the 60-79 group. However, only R-CHOP, younger age, and lower Ann Arbor stage remained independent favorable prognostic factors in the 80+ group. Our population-based study demonstrated the clinical benefits of rituximab and anthracycline in extremely elderly Asian patients with DLBCL.